Purpose: Osteosarcoma (OSA) is the most common malignancy of bone in children and
adolescents. Standard treatments include adjuvant chemotherapy, radiotherapy, hormone or biological
therapy, and if OSA is refractory, surgical ablation of the primary tumor. Advancements in treatment
modalities have led to increased rates of ‘limb-sparing’ surgeries, but patients are still threatened with
the risk of recurrence. New chemotherapeutic delivery systems and strategies are needed to improve
treatment options and patient outcomes.
Methods: Halloysite nanotubes (HNTs) exhibit high levels of cytocompatibility and biocompatibility
and have been show to be effective at sustained drug release. HNTs were coated with the polyelectrolytes
(PE), polyvinylpyrrolidone and polyacrylic acid, and methotrexate (MTX) infused within the coating layers. MTX
release and cytotoxicity studies were used to assess the effectiveness of the coatings in inhibiting osteosarcoma cell
Results: Polyelectrolyte coatings provided sustained release of MTX and, in an in-vitro study, were show to be effective
in altering osteosarcoma cell morphology and reducing the rate of cell proliferation. We further show that MTX-coated
halloysite nanotubes can be added to a polymer, Nylon-6; the MTX released, and still retain its ability to inhibit osteosarcoma
Conclusion: HNT/MTX encapsulated complexes inhibited osteosarcoma cell proliferation and show potential as a delivery
vehicle for the prevention of tumor metastasis and/or tumor recurrence after surgery.